Jundishapur Journal of Microbiology

Published by: Kowsar

Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine

Mohammad-Hassan Pouriayevali 1 , Taravat Bamdad 1 , * , Mohammad-Reza Aghasadeghi 2 , Seyed Mehdi Sadat 2 and Farzaneh Sabahi 1
Authors Information
1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
2 Department of Hepatitis and AIDS, Pasteur Institute of Iran. Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2016, 9 (3); e33909
  • Published Online: March 19, 2016
  • Article Type: Research Article
  • Received: October 18, 2015
  • Revised: December 11, 2015
  • Accepted: January 17, 2016
  • DOI: 10.5812/jjm.33909

To Cite: Pouriayevali M, Bamdad T, Aghasadeghi M, Sadat S M, Sabahi F. Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine, Jundishapur J Microbiol. 2016 ; 9(3):e33909. doi: 10.5812/jjm.33909.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol. 1993; 67(7): 3835-44[PubMed]
  • 2. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine. 2008; 26(49): 6225-31[DOI][PubMed]
  • 3. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol. 2004; 78(3): 1575-81[PubMed]
  • 4. Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther. 1999; 10(5): 759-68[DOI][PubMed]
  • 5. Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006; 13(14): 1110-7[DOI][PubMed]
  • 6. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20: 621-67[DOI][PubMed]
  • 7. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013; 369: 113-42[DOI][PubMed]
  • 8. Krishnadas DK, Ahn JS, Han J, Kumar R, Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol. 2010; 22(6): 491-502[DOI][PubMed]
  • 9. Krishnadas DK, Li W, Kumar R, Tyrrell LJ, Agrawal B. In vitro activation and differentiation of naive CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells. Cell Immunol. 2009; 259(2): 141-9[DOI][PubMed]
  • 10. Pawlotsky JM. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol. 2009; 6(7): 383-5[DOI][PubMed]
  • 11. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol. 2007; 179(7): 4741-53[PubMed]
  • 12. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 1997; 158(5): 2278-84[PubMed]
  • 13. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999; 116(1): 135-43[PubMed]
  • 14. Alvarez-Lajonchere L, Duenas-Carrera S. Advances in DNA immunization against hepatitis C virus infection. Hum Vaccin. 2009; 5(8): 568-71[PubMed]
  • 15. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007; 25(8): 1452-63[DOI][PubMed]
  • 16. Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, et al. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther. 2016; 23(1): 26-37[DOI][PubMed]
  • 17. Yu H, Huang H, Xiang J, Babiuk LA, van Drunen Littel-van den Hurk S. Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol. 2006; 87: 1-10[DOI][PubMed]
  • 18. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol. 2011; 186(4): 2355-64[DOI][PubMed]
  • 19. Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol. 1998; 161(9): 4917-23[PubMed]
  • 20. Gao M, Wang HP, Wang YN, Zhou Y, Wang QL. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo. Vaccine. 2006; 24(26): 5491-7[DOI][PubMed]
  • 21. Lazdina U, Hultgren C, Frelin L, Chen M, Lodin K, Weiland O, et al. Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol. 2001; 82: 1299-308[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments